GW572016 (lapatinib)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Lung Cancer, Non-Small CellNeoplasms, Breast

Phase 2

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

TerminatedNCT00073008

GlaxoSmithKlineLung Cancer, Non-Small Cell

Start: 2003-11-30End: 2008-07-31Updated: 2017-02-28

Phase 3

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

CompletedNCT00075270

GlaxoSmithKlineNeoplasms, Breast

Start: 2004-01-31End: 2012-03-31Updated: 2015-05-06

Related Papers

Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.

Journal of Clinical Oncology2014-05-20

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.

2010-04-0114 citations